Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-178 vs Perjeta in Neoadjuvant HER2+ Breast Cancer
NCT05802225Phase 3Active, not recruiting
- Sponsor
- BIOCAD
- Start
- Jan 2023
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of BCD-178 in HER2-positive breast cancer, sponsored by BIOCAD. Started Jan 2023; status: active, not recruiting.
02
Drugs
BCD-178
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT05802225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05802225.